Company CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
68.16 USD -2.85% Intraday chart for CRISPR Therapeutics AG -6.55% +8.88%

Business Summary

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Number of employees: 407

Sales per Business

USD in Million2022Weight2023Weight Delta
Collaboration
99.7 %
0 36.4 % 370 99.7 % +84,762.39%
Grant
0.3 %
1 63.6 % 1 0.3 % +58.27%

Sales per region

USD in Million2022Weight2023Weight Delta
Switzerland and United States
100.0 %
1 100.0 % 371 100.0 % +30,885.48%

Managers

Managers TitleAgeSince
Chief Executive Officer 45 15-07-31
Director of Finance/CFO 40 23-03-13
Chief Tech/Sci/R&D Officer 67 19-09-30
Chief Tech/Sci/R&D Officer - 17-02-27
Investor Relations Contact - -
Corporate Officer/Principal - 23-01-04
Human Resources Officer - 16-07-31
General Counsel 52 17-04-30

Members of the board

Members of the board TitleAgeSince
Director/Board Member 66 20-06-10
Director/Board Member 46 15-04-28
Director/Board Member 47 15-03-31
Director/Board Member 56 22-06-08
Director/Board Member 72 19-06-10
Director/Board Member 58 19-06-10
Chief Executive Officer 45 15-07-31
Director/Board Member 61 21-06-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 80,446,266 79,131,363 ( 98.37 %) 170,316 ( 0.2117 %) 98.37 %

Shareholders

NameEquities%Valuation
ARK Investment Management LLC
10.14 %
8,536,104 10.14 % 719 M $
Capital Research & Management Co. (International Investors)
7.286 %
6,134,450 7.286 % 517 M $
T. Rowe Price Investment Management, Inc.
4.289 %
3,611,186 4.289 % 304 M $
Nikko Asset Management Co., Ltd.
4.002 %
3,369,762 4.002 % 284 M $
Nikko Asset Management Americas, Inc.
4.002 %
3,369,762 4.002 % 284 M $
BlackRock Institutional Trust Co. NA
2.761 %
2,324,211 2.761 % 196 M $
Fidelity Management & Research Co. LLC
2.185 %
1,839,871 2.185 % 155 M $
1,753,497 2.083 % 148 M $
Vanguard Investments Australia Ltd.
1.889 %
1,590,651 1.889 % 134 M $
NEA Management Co. LLC
1.886 %
1,587,854 1.886 % 134 M $

Company contact information

CRISPR Therapeutics AG

Baarerstrasse 14

6300, Zug

+41 41 561 32 77

http://www.crisprtx.com
address CRISPR Therapeutics AG(CRSP)